Interleukin-8 (IL-8) is a chemokine that has an autocrine and/or paracrine tumor-promoting role and significant potential as a prognostic and/or predictive cancer biomarker. In breast cancer, which is mostly determined by expression of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), IL-8 could play a specific role. IL-8 is highly expressed in ER− breast cancers, but it increases invasiveness and metastatic potential of both ER− and ER+ breast cancer cells. It is also highly expressed in HER2+ breast cancers. Because of the complex crosstalk between these receptors and IL-8, its role is mainly determined by delicate balance in their signaling pathways. Therefore, the main point of this review was to analyze the possible influence of IL-8 in breast cancer progression related to its interaction with ER and HER2 and the consequent therapeutic implications of these relations.
Get full access to this article
View all access options for this article.
References
1.
AcetoN, DussS, MacdonaldG, MeyerDS, RoloffTC, HynesNEet al.2012. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res, 14:R131.
2.
AzenshteinE, MeshelT, ShinaS, BarakN, KeydarI, Ben-BaruchA. 2005. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett, 217:73–86.
3.
BendrikC, DabrosinC. 2009. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol, 182:371–378.
4.
BenoyIH, SalgadoR, Van DamP, EboersK, Van MarckE, ScharpéSet al.2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res, 10:7157–7162.
5.
BratDJ, BellailAC, Van MeirEG. 2005. The role of Interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neurooncology, 7:122–133.
6.
BrewR, EriksonJS, WestDCet al.2000. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine, 12:78–85.
7.
ChaveyC, BibeauF, Gourgou-BourgadeS, BurlinchonS, BoissièreF, LauneDet al.2007. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 9:R15.
8.
Chelouche-LevD, MillerCP, TellezC, RuizM, Bar-EliM, PriceJE. 2004. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer, 40:2509–2518.
9.
ChenY, ShiM, YuG-Z, QinX-R, JinG, ChenPet al.2012. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol, 18:1123–1129.
10.
ColomboPE, MilaneziF, WeigeltB, Reis-FilhoJS. 2011. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res, 13:212.
11.
De LarcoJE, WuertzBR, FurchtLT. 2004. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res, 10:4895–4900.
12.
De LarcoJE, WuertzBR, RosnerKA, EricksonSA, GamacheDE, ManivelJC, FurchtLT. 2001. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol, 158:639–646.
13.
De LarcoJE, WuertzBR, YeeD, RickertBL, FurchtLT. 2003. Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc Natl Acad Sci U S, A100:13988–13993.
14.
DuanZ, FellerAJ, PensonRT, ChabnerBA, SeidenMV. 1999. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res, 5:3445–3453.
15.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378:771–784.
16.
EwingtonL, TaylorA, SriraksaR, HorimotoY, LamEW, El-BahrawyMA. 2012. The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma. Cytokine, 59:417–422.
17.
FernandoRI, CastilloMD, LitzingerM, HamiltonDH, PalenaC. 2011. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res, 71:5296–5306.
18.
FreundA, ChauveauC, BrouilletJP, LucasA, LacroixM, LicznarAet al.2003. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene, 22:256–265.
19.
FreundA, JolivelV, DurandS, KersualN, ChalbosD, ChaveyCet al.2004. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene, 23:6105–6114.
20.
GinestierC, LiuS, DiebelME, KorkayaH, LuoM, BrownMet al.2010. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest, 120:485–497.
HaimK, WeitzenfeldP, MeshelT, Ben-BaruchA. 2011. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia, 13:230–243.
23.
HayesE, NicholsonRI, HiscoxS. 2011. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci, 16:838–848.
24.
HolmesWE, LeeJ, KuangWJ, RiceGC, WoodWI. 1991. Structure and functional expression of a human interleukin-8 receptor. Science, 253:1278–1280.
25.
InoueK, SlatonJW, EveBY, KimSJ, PerrotteP, BalbayMD. 2000a. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res, 6:2104–2119.
26.
InoueK, SlatonJW, KimSJ, PerrotteP, EveBY, Bar-EliM, RadinskyR, DinneyCP. 2000b. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res, 60:2290–2299.
27.
KeeleyEC, MehradB, StrieterRM. 2010. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res, 106:91–111.
28.
KnallC, YoungS, NickJA, BuhlAM, WorthenGS, JohnsonGL. 1996. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J Biol Chem, 271:2832–2838.
29.
KotyzaJ. 2012. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review. Int J Biol Markers, 27:e169–e178.
30.
LagiouP, TrichopoulosD. 2011. Inflammatory biomarkers and risk of lung cancer Pagona lagiou and dimitrios trichopoulos. J Natl Cancer Inst, 103:1073–1075.
31.
LeeYS, ChoiI, NingY, KimNY, KhatchadourianV, YangDet al.2012. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer, 106:1833–1841.
32.
LiA, DubeyS, VarneyML, DaveBJ, SinghRK. 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol, 170:3369–3376.
33.
LiA, VarneyML, ValasekJ, GodfreyM, DaveBJ, SinghRK. 2005. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis, 8:63–71.
34.
LiXJ, PengLX, ShaoJY, LuWH, ZhangJX, ChenSet al.2012. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis, 33:1302–1309.
35.
LinY, HuangR, ChenL, LiS, ShiQ, JordanCet al.2004. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer, 109:507–515.
36.
LinY, WangSM, HuangRP. 2005. Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor. Zhonghua Yi Xue Za Zhi, 85:1419–1423.
37.
MartinD, GalisteoR, GutkindJS. 2009. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1complex. J Biol Chem, 284:6038–6042.
38.
MillerLJ, KurtzmanSH, WangYet al.1998. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res, 18:77–81.
39.
MiyamotoM, ShimizuY, OkadaKet al.1998. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother, 47:47–57.
40.
MohamedMM. 2012. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway. Cell Commun Signal, 10:3.
41.
NastaseA, PâslaruL, NiculescuAM, IonescuM, DumitraşcuT, HerleaVet al.2011. Prognostic and predictive potential molecular biomarkers in colon cancer. Chirurgia (Bucur), 106:177–185.
42.
NingY, ManegoldPC, HongYK, ZhangW, PohlA, LurjeGet al.2011. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer, 128:2038–2049.
43.
OpdenakkerG, Van DammeJ. 2004. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol, 48:519–527.
44.
OsborneCK. 1998. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat, 51:227–238.
45.
PapaxoinisG, PectasidesDG, KorantzisI, KoutrasA, KosmidisPA, LinardouHet al.2010. Plasma angiogenic markers in patients with metastatic breast cancer treated with weekly docetaxel. J Clin Oncol, 28:e21004.
46.
PariseCA, BauerKR, BrownMM, CaggianoV. 2009. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J, 15:593–602.
47.
PatelPS, VarneyML, DaveBJ, SinghRK. 2002. Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. J Interferon Cytokine Res, 22:427–435.
48.
PianettiS, ArsuraM, Romieu-MourezR, CoffeyRJ, SonensheinGE. 2001. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene, 20:1287–99.
49.
PratA, BaselgaJ. 2008. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol, 5:531–542.
50.
PremkumarVG, YuvarajS, VijayasarathyK, GangadaranSG, SachdanandamP. 2007. Serum cytokine levels of interleukin-1beta, −6, −8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin Pharmacol Toxicol, 100:387–391.
51.
RichmondA, YangJ, SuY. 2009. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res, 22:175–186.
52.
RodyA, KarnT, LiedtkeC, PusztaiL, RuckhaeberleE, HankerLet al.2011. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res, 13:R97.
53.
RussellK, HungM-C. 1992. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res, 52:6624–6629.
54.
SandhuR, ParkerJS, JonesWD, LivasyCA, ColemanWB. 2010. Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. LabMedicine, 41:364–372.
SharmaB, SinghRK. 2011. Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinogen, 10:36.
57.
SheridanC, KishimotoH, FuchsRK, MehrotraS, Bhat-NakshatriP, TurnerCHet al.2006. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res, 8:R59.
58.
SinghB, BerryJA, ShoherA, LucciA. 2006. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res, 131:267–275.
59.
SinghJK, FarnieG, BundredNJ, SimoesBM, ShergillA, LandbergG, HowellSJ, ClarkeRB. 2013. Targetting CXCR½ significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res, 19:643–656.
60.
SinghRK, GutmanM, RadinskyR, BucanaCD, FidlerIJ. 1994. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res, 54:3242–3247.
61.
SinghRK, LokeshwarBL. 2009. Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer, 8:57.
62.
SinghS, ShiQ, BaileyST, PalczewskiMJ, PardeeAB, IglehartJDet al.2007. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther, 6:1973–1982.
63.
SinghS, SinghAP, SharmaB, OwenLB, SinghRK. 2010. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol, 6:111–116.
64.
SnoussiK, MahfoudhW, BouaouinaN, FekihM, KhairiH, HelalANet al.2010. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer, 10:283.
65.
UrquidiV, ChangM, DaiY, KimJ, WolfsonED, GoodisonSet al.2012. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol, 12:12.
66.
VandercappellenJ, Van DammeJ, StruyfS. 2008. The role of CXC chemokines and their receptors in cancer. Cancer Lett, 267:226–244.
67.
Vazquez-MartinA, ColomerR, MenendezJA. 2007. Protein array technology to detect HER2 (erbB-2)-induced ‘cytokine signature’ in breast cancer. Eur J Cancer, 43:1117–1124.
68.
VenkatakrishnanG, SalgiaR, GroopmanJE. 2000. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem, 275:6868–6875.
69.
WangY, GuoXQ, NiuXL, WuJ, ZhuYQ, MaoLQ. 2010. Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 1:21–24.
70.
WangY, YangJ, GaoY, DuY, BaoL, NiuWet al.2005. Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol, 2:365–272.
71.
WaughDJJ, WilsonC. 2008. The interleukin-8 pathway in cancer. Clin Cancer Res, 14:6735.
72.
WenXF, YangG, MaoW, ThorntonA, LiuJ, BastRC.Jr, LeXF. 2006. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene, 25:6986–6996.
73.
YangJ, WangY, GaoY, ShaoJ, ZhangXJ, YaoZ. 2009. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine, 46:382–391.
74.
YangW, Li-PaiC, HuangR, HuangR-P. 2005. Inhibition of IL-6 and IL-8 enhances chemosensitization in multidrug resistant human breast cancer cells. Proc Amer Assoc Cancer Res, 46Abstract No.5079.
75.
YaoC, LinY, YeCS, BiJ, ZhuYF, WangSM. 2007. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl), 120:1766–1772.
76.
YuanA, ChenJJ, YaoPL, YangPC. 2005. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci, 10:853–865.
77.
ZuccariDA, LeonelC, CastroR, GelaletiGB, JardimBV, MoschetaMGet al.2012. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem, 114:571–576.
